In this study, we evaluated the characteristics of clinical studies supporting the European Medicines Agency approval of new cancer medicines from 2009 to 2016. In addition, we determined the proportion of drugs with demonstrable benefit on survival or quality of life over available treatment options or placebo, both at time of approval and in the postmarking period. Finally, we investigated the magnitude of benefit of drugs showing a significant improvement on survival in the treatment of cancers.
Huseyin Naci, MHS, PhD, is a 2018–19 U.K. Harkness Fellow in Health Care Policy and Practice at the Harvard Kennedy School of Government and Harvard Medical School. Also, he is an Assistant Professor of Health Policy at the London School of Economics and Political Science (LSE), where he conducts research and teaches on health policy and practice in Europe and the U.S. Dr. Naci also serves as the Director of LSE’s Executive M.Sc. program in Health Economics, Outcomes and Management in Cardiovascular Sciences.